Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

# Drug Oversight Sought for Nutraceuticals

**By Health Desk Correspondent, The National Briefing** | April 19, 2026

On Sunday, a prominent health advocacy NGO formally petitioned the Union Health Ministry to shift the regulatory oversight of nutraceuticals from food authorities to the national drug regulator. Flagging severe concerns over unregulated pricing and compromised product quality, the civil society group argued that the booming dietary supplement industry exploits a regulatory grey area. This April 2026 appeal highlights an urgent need for the Central Drugs Standard Control Organisation (CDSCO) to intervene, ensuring products marketed for therapeutic benefits face strict clinical scrutiny and price caps to protect Indian consumers from unsafe and exploitative practices. [Source: Hindustan Times | Additional: General Health Policy Context].

## The Regulatory Loophole: Food vs. Medicine

For over a decade, the Indian nutraceutical market—comprising vitamins, minerals, botanical extracts, and dietary supplements—has operated under the purview of the Food Safety and Standards Authority of India (FSSAI). Because these products are legally classified as “foods for special dietary uses” rather than pharmaceuticals, they are exempt from the rigorous clinical trials, efficacy testing, and strict pharmacovigilance required for standard allopathic medicines.

The NGO’s petition, submitted over the weekend, highlights this critical jurisdictional gap. While FSSAI focuses on basic food safety and ensuring products contain ingredients generally recognized as safe (GRAS), it lacks the infrastructure to evaluate therapeutic claims. Consequently, consumers are flooded with products promising to manage diabetes, lower cholesterol, or cure joint pain, without the robust scientific backing demanded of actual pharmaceuticals.

“We are witnessing a dangerous blurring of lines between nutrition and medicine,” noted a lead researcher affiliated with the petitioning NGO. “When a patient takes a high-dose vitamin or a concentrated herbal extract to treat a specific deficiency or ailment, they are using it as a drug. It is imperative that the CDSCO steps in to evaluate these products with a pharmaceutical lens.” [Source: Hindustan Times | Additional: Public Health Advocacy Reports].

## Quality Concerns and Adulteration Risks

Perhaps the most alarming aspect of the NGO’s report is the documentation of widespread quality control failures within the dietary supplement sector. Without CDSCO oversight, the barrier to entry for manufacturing nutraceuticals remains remarkably low.

Independent laboratory testing cited in the petition revealed several disturbing trends:
* **Active Pharmaceutical Ingredient (API) Spiking:** Several supposedly “all-natural” weight loss and bodybuilding supplements were found secretly laced with banned pharmaceutical compounds like sibutramine or unprescribed anabolic steroids.
* **Heavy Metal Contamination:** Botanical extracts frequently exhibited unsafe levels of lead, arsenic, and mercury, primarily due to poor sourcing of raw materials and inadequate purification processes.
* **Ingredient Inconsistency:** Routine batch testing showed that the actual concentration of active ingredients often varied wildly from what was printed on the label, rendering the products either ineffective or potentially toxic.

Dr. Arundhati Sen, an independent clinical pharmacologist not directly involved with the petition, echoed these concerns. “The lack of Good Manufacturing Practices (GMP) comparable to schedule M of the Drugs and Cosmetics Act means that the nutraceutical you buy today might be fundamentally different from the one you buy next month. We desperately need standardized, pharmaceutical-grade quality assurance for any product making physiological claims.”

## The Pricing Paradox: Evading Price Controls

Beyond safety, the financial exploitation of patients forms the crux of the NGO’s argument. In India, essential medicines and traditional pharmaceuticals are subject to stringent price capping through the Drug Price Control Order (DPCO), monitored by the National Pharmaceutical Pricing Authority (NPPA). This ensures life-saving and standard therapeutic drugs remain affordable to the masses.

Nutraceuticals entirely bypass the DPCO. Because they are legally “food,” manufacturers can dictate Maximum Retail Prices (MRP) based solely on market demand and aggressive marketing, leading to exorbitant profit margins.

The NGO’s comparative analysis presented staggering discrepancies:
* A standard Vitamin D3 (60,000 IU) tablet regulated as a pharmaceutical drug typically costs between ₹15 to ₹25.
* The exact same dosage, formulated as a “gummy” or a “health supplement” under an FSSAI license, often retails for ₹80 to ₹150.
* Similar extreme price multipliers were observed for Vitamin B12, Iron supplements, and Omega-3 fatty acids.

By intentionally registering their products as dietary supplements rather than drugs, pharmaceutical conglomerates and independent wellness brands effectively sidestep the NPPA. The petition urges the government to immediately categorize high-dose vitamins and therapeutic botanicals under the National List of Essential Medicines (NLEM), subjecting them to immediate price ceilings. [Source: Hindustan Times | Additional: NPPA Pricing Guidelines 2025-2026].

## Market Boom Amplifies the Urgency

The push for tighter regulation comes at a time when the Indian nutraceutical market is experiencing unprecedented, exponential growth. Propelled by a post-pandemic surge in preventive healthcare awareness, rising disposable incomes, and the proliferation of e-commerce wellness platforms, the sector has transformed from a niche market into a multi-billion-dollar juggernaut.

**Projected Indian Nutraceutical Market Segmentation (2026 Estimates):**

| Segment | Estimated Market Share | Key Drivers |
| :— | :— | :— |
| **Vitamins & Minerals** | 35% | Immunity boosting, dietary deficiencies, corporate wellness. |
| **Herbal & Botanicals** | 30% | Ayurvedic integration, organic health trends, holistic healing. |
| **Protein & Amino Acids** | 25% | Fitness industry growth, sports nutrition, geriatric care. |
| **Probiotics & Gut Health** | 10% | Rising digestive disorders, advanced microbiome research. |

*Data Context: Industry estimates suggest the Indian nutraceutical market has crossed the $15 billion mark as of early 2026, registering an annual growth rate of over 18%.*

With millions of citizens consuming these products daily, the NGO argues that treating nutraceuticals with the same regulatory leniency as standard food items like biscuits or juices is no longer a tenable public health strategy. The sheer volume of consumption magnifies the statistical probability of adverse health events linked to poor quality control.

## Global Precedents and the Need for Harmonization

The regulatory friction between food authorities and drug regulators regarding supplements is not unique to India. Globally, health ministries have struggled to classify and police the nutraceutical space, though several nations have evolved hybrid regulatory frameworks that India could emulate.

In the United States, the FDA regulates supplements under the Dietary Supplement Health and Education Act (DSHEA). While frequently criticized for being too lenient prior to market entry, the FDA strictly enforces post-market surveillance and penalizes brands making unverified disease-curing claims.

Conversely, Australia’s Therapeutic Goods Administration (TGA) employs a much stricter model. Supplements are classified as “complementary medicines” and must be entered into the Australian Register of Therapeutic Goods (ARTG). They undergo rigorous safety and quality evaluations before they can legally be sold.

The Indian NGO is advocating for a framework akin to the Australian model. They propose a joint task force comprising officials from the FSSAI, the CDSCO, and the Ministry of Ayush to create a specific “Therapeutic Supplements” classification. This would mandate pharmaceutical-grade manufacturing standards and NPPA price monitoring without subjecting low-risk multivitamins to full-scale clinical trials meant for novel synthetic drugs.

## Industry Pushback and Perspectives

Unsurprisingly, the push for CDSCO oversight has triggered immediate pushback from the nutraceutical and wellness industry. Manufacturers warn that reclassifying dietary supplements as drugs could devastate a thriving economic sector, stifle innovation, and ultimately drive up costs for the average consumer by introducing layers of bureaucratic red tape.

Rajiv Mehta, a representative for a prominent national association of dietary supplement manufacturers, voiced strong opposition to the NGO’s demands. “The FSSAI framework, especially with the updated 2024 nutraceutical regulations, is already robust and aligned with global Codex Alimentarius standards. Forcing MSMEs (Micro, Small, and Medium Enterprises) to comply with CDSCO’s pharmaceutical protocols will wipe out thousands of legitimate wellness businesses.”

Industry advocates argue that while isolated incidents of adulteration do occur, they are the result of rogue operators, not systemic failures. They suggest that instead of shifting jurisdictions, the government should focus on empowering FSSAI with better funding, more testing laboratories, and stricter penal powers to crack down on bad actors. [Source: Hindustan Times | Additional: Industry Consortium Statements].

## Conclusion: Balancing Innovation and Public Safety

As the lines between food and medicine continue to blur, the Indian government faces a complex policy dilemma. The April 2026 petition serves as a critical catalyst for a long-overdue debate on the safety, efficacy, and economic fairness of the nutraceutical industry.

While the wellness sector undeniably plays a vital role in preventive healthcare, the NGO’s evidence regarding rampant adulteration, misleading health claims, and predatory pricing cannot be ignored. The lack of synergy between the FSSAI, the CDSCO, and the NPPA has created a loophole that currently prioritizes corporate profit margins over patient safety.

Moving forward, the Union Health Ministry is expected to constitute an inter-ministerial expert committee to review the NGO’s findings. Whether this leads to a complete regulatory overhaul, bringing supplements under the stringent umbrella of the Drugs and Cosmetics Act, or results in a specialized hybrid regulatory body remains to be seen. However, one consensus is clear: as Indian consumers increasingly turn to nutraceuticals for their well-being, the demand for transparency, safety, and fair pricing has never been more urgent.